Cargando…

Beyond taxanes: the next generation of microtubule-targeting agents

Taxanes are a standard first-line option for metastatic breast cancer (MBC), but their utility may be limited by primary or acquired resistance. New microtubule-targeting agents have been developed to overcome taxane resistance and provide additional options for improving patient outcomes. This arti...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortes, Javier, Vidal, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3387492/
https://www.ncbi.nlm.nih.gov/pubmed/22113255
http://dx.doi.org/10.1007/s10549-011-1875-6
_version_ 1782237097268084736
author Cortes, Javier
Vidal, Maria
author_facet Cortes, Javier
Vidal, Maria
author_sort Cortes, Javier
collection PubMed
description Taxanes are a standard first-line option for metastatic breast cancer (MBC), but their utility may be limited by primary or acquired resistance. New microtubule-targeting agents have been developed to overcome taxane resistance and provide additional options for improving patient outcomes. This article reviews these alternative microtubule-targeting agents and their potential clinical benefits for MBC patients. Relevant clinical data were compiled through searches within PubMed and congress abstract databases. Ixabepilone, a novel microtubule-stabilizing drug approved by the US Food and Drug Administration (FDA), has proven efficacy across multiple lines of therapy, including patients with taxane-resistant/refractory disease. In phase III trials, ixabepilone plus capecitabine significantly improved progression-free survival compared with capecitabine alone in anthracycline/taxane-pretreated patients. Eribulin has recently been approved by the FDA and by the European Medicines Agency for the treatment of patients with MBC who have received at least two prior chemotherapy regimens for late-stage disease. In a phase III trial, eribulin extended overall survival compared with the physician’s treatment choice in heavily pretreated MBC patients. In addition, several investigational microtubule-targeting agents may have therapeutic potential in MBC. The development of new microtubule-targeting agents helps to address the need for additional effective regimens for patients progressing after standard treatment with anthracycline- and taxane-containing regimens.
format Online
Article
Text
id pubmed-3387492
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-33874922012-07-11 Beyond taxanes: the next generation of microtubule-targeting agents Cortes, Javier Vidal, Maria Breast Cancer Res Treat Review Taxanes are a standard first-line option for metastatic breast cancer (MBC), but their utility may be limited by primary or acquired resistance. New microtubule-targeting agents have been developed to overcome taxane resistance and provide additional options for improving patient outcomes. This article reviews these alternative microtubule-targeting agents and their potential clinical benefits for MBC patients. Relevant clinical data were compiled through searches within PubMed and congress abstract databases. Ixabepilone, a novel microtubule-stabilizing drug approved by the US Food and Drug Administration (FDA), has proven efficacy across multiple lines of therapy, including patients with taxane-resistant/refractory disease. In phase III trials, ixabepilone plus capecitabine significantly improved progression-free survival compared with capecitabine alone in anthracycline/taxane-pretreated patients. Eribulin has recently been approved by the FDA and by the European Medicines Agency for the treatment of patients with MBC who have received at least two prior chemotherapy regimens for late-stage disease. In a phase III trial, eribulin extended overall survival compared with the physician’s treatment choice in heavily pretreated MBC patients. In addition, several investigational microtubule-targeting agents may have therapeutic potential in MBC. The development of new microtubule-targeting agents helps to address the need for additional effective regimens for patients progressing after standard treatment with anthracycline- and taxane-containing regimens. Springer US 2011-11-24 2012 /pmc/articles/PMC3387492/ /pubmed/22113255 http://dx.doi.org/10.1007/s10549-011-1875-6 Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Review
Cortes, Javier
Vidal, Maria
Beyond taxanes: the next generation of microtubule-targeting agents
title Beyond taxanes: the next generation of microtubule-targeting agents
title_full Beyond taxanes: the next generation of microtubule-targeting agents
title_fullStr Beyond taxanes: the next generation of microtubule-targeting agents
title_full_unstemmed Beyond taxanes: the next generation of microtubule-targeting agents
title_short Beyond taxanes: the next generation of microtubule-targeting agents
title_sort beyond taxanes: the next generation of microtubule-targeting agents
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3387492/
https://www.ncbi.nlm.nih.gov/pubmed/22113255
http://dx.doi.org/10.1007/s10549-011-1875-6
work_keys_str_mv AT cortesjavier beyondtaxanesthenextgenerationofmicrotubuletargetingagents
AT vidalmaria beyondtaxanesthenextgenerationofmicrotubuletargetingagents